InterPAD - DETAILS

Talazoparib, 1207456-01-6, BMN-673, BMN 673, BMN673, Talazoparib (BMN 673), Talzenna, (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one, LT-673, UNII-9QHX048FRV, 9QHX048FRV, (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One, 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-, (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one, (8S,9R)-BMN 673, (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one, Talazoparib [USAN:INN], talazoparibum, C19H14F2N6O, 4pjt, (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-2,7,8,9-TETRAHYDRO-3H-PYRIDO(4,3,2-DE)PHTHALAZIN-3-ONE, 2YQ, TALAZOPARIB [MI], Talazoparib(BMN-673), TALAZOPARIB [INN], Talazoparib (USAN/INN), TALAZOPARIB [USAN], Talazoparib (BMN-673), Talazoparib(BMN-673)?, TALAZOPARIB [WHO-DD], GTPL8313, SCHEMBL2299348, CHEMBL3137320, BMN673,BMN-673, L01XX60, CHEBI:231344, HWGQMRYQVZSGDQ-HZPDHXFCSA-N, DTXSID001025928, AMY27900, EX-A1356, BDBM50084621, MFCD22666357, NSC767125, AKOS027250735, AKOS040758983, CS-0937, DB11760, NSC-767125, NCGC00351600-09, NCGC00390231-01, AC-30927, AS-57491, HY-16106, LT 00673, NS00072968, S7048, SW219655-1, PF-06944076, D10732, A892079, EN300-20176329, Q25100990, Q27453411, (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(1-methyl-1H-1,2,4-triazol-5-yl)-2,3,10-triazatricyclo[7.3.1.0,5,13]trideca-1,5,7,9(13)-tetraen-4-one, (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;BMN-673, Talazoparib; (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazin-3-one

No.	Title	Href
1	Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux. Biochem Pharmacol. 2022 May;199:115024. doi: 10.1016/j.bcp.2022.115024.	`Click`

No.

Title

Href

Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux. Biochem Pharmacol. 2022 May;199:115024. doi: 10.1016/j.bcp.2022.115024.

Click

Name	Talazoparib
PubChem CID	135565082
Molecular Weight	380.4g/mol
Synonyms	Talazoparib, 1207456-01-6, BMN-673, BMN 673, BMN673, Talazoparib (BMN 673), Talzenna, (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one, LT-673, UNII-9QHX048FRV, 9QHX048FRV, (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One, 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-, (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one, (8S,9R)-BMN 673, (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one, Talazoparib [USAN:INN], talazoparibum, C19H14F2N6O, 4pjt, (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-2,7,8,9-TETRAHYDRO-3H-PYRIDO(4,3,2-DE)PHTHALAZIN-3-ONE, 2YQ, TALAZOPARIB [MI], Talazoparib(BMN-673), TALAZOPARIB [INN], Talazoparib (USAN/INN), TALAZOPARIB [USAN], Talazoparib (BMN-673), Talazoparib(BMN-673)?, TALAZOPARIB [WHO-DD], GTPL8313, SCHEMBL2299348, CHEMBL3137320, BMN673,BMN-673, L01XX60, CHEBI:231344, HWGQMRYQVZSGDQ-HZPDHXFCSA-N, DTXSID001025928, AMY27900, EX-A1356, BDBM50084621, MFCD22666357, NSC767125, AKOS027250735, AKOS040758983, CS-0937, DB11760, NSC-767125, NCGC00351600-09, NCGC00390231-01, AC-30927, AS-57491, HY-16106, LT 00673, NS00072968, S7048, SW219655-1, PF-06944076, D10732, A892079, EN300-20176329, Q25100990, Q27453411, (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(1-methyl-1H-1,2,4-triazol-5-yl)-2,3,10-triazatricyclo[7.3.1.0,5,13]trideca-1,5,7,9(13)-tetraen-4-one, (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one;BMN-673, Talazoparib; (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazin-3-one
Drug Type	Small molecule
Formula	C₁₉H₁₄F₂N₆O
SMILES	CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
InChI	1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
InChIKey	HWGQMRYQVZSGDQ-HZPDHXFCSA-N
CAS Number	1207456-01-6
ChEMBL ID	CHEMBL3137320
TTD ID	D0GV8J
Drug Bank ID	DB11760
KEGG ID	D10732
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Resveratrol, Talazoparib
Partner Name	Resveratrol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	ATG5	hsa9474
	Up-regulation	Expression	ATG7	hsa10533
	Down-regulation	Expression	HR	hsa55806
	Down-regulation	Expression	MAP1LC3A	hsa84557
	Down-regulation	Expression	MAP1LC3B	hsa81631
	Up-regulation	Expression	MAPK14	hsa1432
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vivo Model	Exponentially growing MCF-7 cells (5×10⁶ per mouse) were injected subcutaneously into the flank of 6 weeks old female SCID mice (weighing 25-35 g, 5 mice per group).
Result	Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux